In order to examine the potential role of CAF-200 in the acquisition of resistance to anti-HER2 therapy by tumour cells, we measured the effect that secretions of CAFs into the CM generated on HER2-positive breast cancer, under TPD treatment conditions. The gene discussed is ERBB2; the disease is breast carcinoma.